Harmony Biosciences Holdings Inc

HRMY remains in a Stage 2 advancing uptrend with rising EMAs, but a Bullish Exhaustion pattern signals weakening upside momentum and a likely pullback. Price is marginally retracing into the rising 9/21 EMA zone without clear breakdown, so execution is deferred. We will watch for a firm acceptance off the 9/21 EMA area for a buy aligned with the medium-term bullish structure.

• ↑Q2 revenue $261.3M (+30% YoY, +21% QoQ); net income $75.4M ($1.28 EPS)
• ↑$963M cash position funds pipeline and business development
• ↓Weak profitability factor warns of limited margin conversion